Hints and tips:
Showing results for Craig v. Takeda Pharmaceuticals America Inc
Related Special Reports
...Goldman, Bank of America, JPMorgan Chase, Morgan Stanley, Citi and UBS are on the deal....
...Craig Garthwaite, professor of hospital and health services at Northwestern University, says it is “terrible” that the FDA has bowed to patient pressure groups and not listened to its scientific advisers...
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...The latest acquisition contributes to a record year for Japanese outbound deals, led by Takeda Pharmaceutical’s £46bn agreement to buy Irish drugmaker Shire in April....
...Others focused on the significance of Takeda’s move for its country’s pharmaceuticals industry....
...david.crow@ft.com Letter in response to this column: Cheaper alternatives are challenging big pharma / From Craig Sams, Hastings, E Sussex, UK...
...The combined value of those deals — which include Takeda Pharmaceutical’s ¥7tn planned takeover of Shire — was around ¥11.7tn....
...Separately, Japan’s Takeda Pharmaceutical has reached a preliminary agreement to buy Irish drugmaker Shire for about £46bn, a deal that could spark a renewed wave of “big pharma” deals....
...Corporate giants including US cable group Comcast, wireless provider T-Mobile and Japan’s pharmaceutical maker Takeda reached for M&A to head off competitive threats and expand their businesses....
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...In the latest sign of how eager boardrooms are sparking a record number of “megadeals”, Japan’s top drugmaker Takeda revealed it was weighing a $40bn takeover of Irish rival Shire....
...Separately, Hikma disclosed on Thursday that it will expand its licensing and distribution pact with Japan’s Takeda Pharmaceuticals that will add new products to its Middle East and North Africa portfolio...
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...Thomas Sheehan, head of global healthcare at Bank of America Merrill Lynch, said despite the slowdown the fundamentals for dealmaking remained unchanged and activity was bound to pick up again....
...Cancer drug maker Takeda Pharmaceutical, fell 2.6 per cent following Trump’s comments....
..., the pharmaceutical company....
...In Japan, Takeda Pharmaceutical slid 2.7 per cent, Astellas Pharma fell 3.9 per cent and Shionogi sank 3.7 per cent on Thursday morning, while in Australia biotech company CSL Ltd dropped 1.4 per cent and...
...For GlaxoSmithKline and AstraZeneca — twin pillars of Britain’s pharmaceuticals sector — 2016 promises to be a critical year....
...The investment came a day after AstraZeneca agreed to pay Takeda of Japan $575m for a portfolio of respiratory medicines and a month after it bought ZS Pharma, a US biotech company, for $2.7bn....
...Match Group, Inc....
...On Tuesday VW’s core passenger car brand therefore said that “as soon as possible” it would switch to using a different diesel emissions control technology in Europe and North America known as selective...
...Cash-rich Japanese drugmakers have been on a spending spree ahead of the so-called “patent cliff”, highlighted by Takeda Pharmaceutical’s $13.7bn purchase of Nycomed, the Swiss drugmaker, in 2011....
...In March, Craig Venter, the biotech entrepreneur best known for sequencing the human genome, launched a venture called Human Longevity with similar aims to Calico. ——————————————- Letter in response to...
...Another is Human Longevity, founded by Craig Venter, the celebrated US geneticist, with the goal of “expanding a healthier, high performing, more productive lifespan”....
International Edition